Abstract
Endometrial cancers (EC) mutated in the exonuclease domain of the polymerase epsilon gene (POLE mut) accounts for 8-10% of EC and have an excellent outcome. POLE sequencing is not routinely performed but emerging guidelines suggest that POLE mut stage I–II EC may spare adjuvant treatment while advanced POLE mut EC are eligible for a check point inhibitor. Given its therapeutic impact, we aimed at identifying surrogate pathological markers suggesting POLE mut.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
